Human interferon beta

Generic Name: Human interferon beta

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 74899-71-1

Unique Ingredient Identifier: V9GU1EM8SF

Background: Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life.

Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus. Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS). It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.

Indication: This drug is indicated to treat relapsing forms of Multiple Sclerosis (MS) in adults, which includes clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.

Associated Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)

Associated Therapies: -

Clinical Trials

Synairgen backer ready to pump £18-£19 million into phase II trial

Synairgen PLC plans to raise up to £25 million to fund SNG001 development, an inhaled interferon beta treatment for respiratory viral infections. TFG Asset Management backs the initiative, acquiring shares at a 47% discount. The funds will support a phase II trial in mechanically ventilated patients, aiming to reduce mortality rates. The investment also positions SNG001 for potential partnerships. If fundraising fails to meet the £2.9 million minimum, Synairgen may delist from AIM.

telegrafi.com

a month ago

Three professors become 'overnight' millionaires, after a 'major breakthrough' in medicine

Three university professors, Ratko Djukanovic, Stephen Holgate, and Donna Davies, became millionaires after their company, Synairgen, achieved a 3,000% share increase due to a successful COVID-19 drug trial. The drug, SNG001, administered via inhaler, showed significant recovery and reduced severe illness rates in patients.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy